Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib

被引：32

作者：

Hiraoka, Atsushi ^{[1
]}

Kumada, Takashi ^{[2
]}

Tada, Toshifumi ^{[3
]}

Hirooka, Masashi ^{[4
]}

Kariyama, Kazuya ^{[5
]}

Tani, Joji ^{[6
]}

Atsukawa, Masanori ^{[7
]}

Takaguchi, Koichi ^{[8
]}

Itobayashi, Ei ^{[9
]}

Fukunishi, Shinya ^{[10
]}

Tsuji, Kunihiko ^{[11
]}

Ishikawa, Toru ^{[12
]}

Tajiri, Kazuto ^{[13
]}

Ochi, Hironori ^{[14
]}

Yasuda, Satoshi ^{[15
]}

Toyoda, Hidenori ^{[15
]}

Ogawa, Chikara ^{[16
]}

Nishimura, Takashi ^{[17
]}

Hatanaka, Takeshi ^{[18
]}

Kakizaki, Satoru ^{[19
]}

Shimada, Noritomo ^{[20
]}

Kawata, Kazuhito ^{[21
]}

Naganuma, Atsushi ^{[22
]}

Kosaka, Hisashi ^{[23
]}

Shibata, Hiroshi ^{[24
]}

Aoki, Tomoko ^{[25
]}

Tanaka, Takaaki ^{[1
]}

Ohama, Hideko ^{[1
,10
]}

Nouso, Kazuhiro ^{[5
]}

Morishita, Asahiro ^{[6
]}

Tsutsui, Akemi ^{[7
]}

Nagano, Takuya ^{[8
]}

Itokawa, Norio ^{[7
]}

Okubo, Tomomi ^{[7
]}

Arai, Taeang ^{[7
]}

Imai, Michitaka ^{[12
]}

Koizumi, Yohei ^{[4
]}

Nakamura, Shinichiro ^{[3
]}

Joko, Kouji ^{[14
]}

Iijima, Hiroko ^{[17
]}

Kaibori, Masaki ^{[23
]}

Hiasa, Yoichi ^{[4
]}

Kudo, Masatoshi ^{[25
]}

机构：

[1] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, 83 Kasuga Cho, Matsuyama, Ehime 7900024, Japan

[2] Gifu Kyoritsu Univ, Dept Nursing, Ogaki, Japan

[3] Japanese Red Cross Himeji Hosp, Dept Internal Med, Himeji, Hyogo, Japan

[4] Ehime Univ, Dept Gastroenterol & Metabol, Grad Sch Med, Toon, Japan

[5] Okayama City Hosp, Dept Gastroenterol, Okayama, Japan

[6] Kagawa Univ, Dept Gastroenterol & Hepatol, Takamatsu, Kagawa, Japan

[7] Nippon Med Sch, Div Gastroenterol & Hepatol, Dept Internal Med, Tokyo, Japan

[8] Kagawa Prefectural Cent Hosp, Dept Hepatol, Takamatsu, Kagawa, Japan

[9] Asahi Gen Hosp, Dept Gastroenterol, Asahi, Japan

[10] Osaka Med & Phamaceut Univ, Dept Gastroenterol, Osaka, Japan

[11] Teine Keijinkai Hosp, Ctr Gastroenterol, Sapporo, Hokkaido, Japan

[12] Saiseikai Niigata Hosp, Dept Gastroenterol, Niigata, Japan

[13] Toyama Univ Hosp, Dept Gastroenterol, Toyama, Japan

[14] Japanese Red Cross Matsuyama Hosp, Hepatobiliary Ctr, Matsuyama, Ehime, Japan

[15] Ogaki Municipal Hosp, Dept Gastroenterol & Hepatol, Ogaki, Japan

[16] Japanese Red Cross Takamatsu Hosp, Dept Gastroenterol, Takamatsu, Kagawa, Japan

[17] Hyogo Coll Med, Dept Gastroenterol & Hepatol, Nishinomiya, Hyogo, Japan

[18] Gunma Saiseikai Maebashi Hosp, Dept Gastroenterol, Gunma, Japan

[19] Natl Hosp Org Takasaki Gen Med Ctr, Dept Clin Res, Takasaki, Gumma, Japan

[20] Otakanomori Hosp, Div Gastroenterol & Hepatol, Kashiwa, Chiba, Japan

[21] Hamamatsu Univ Sch Med, Hepatol Div, Dept Internal Med 2, Hamamatsu, Shizuoka, Japan

[22] Natl Hosp Org Takasaki Gen Med Ctr, Dept Gastroenterol, Takasaki, Gumma, Japan

[23] Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan

[24] Tokushima Prefectural Cent Hosp, Dept Gastroenterol, Tokushima, Japan

[25] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

来源：

CANCER MEDICINE | 2023年 / 12卷 / 01期

关键词：

atezolizumab plus bevacizumab; hepatocellular carcinoma; lenvatinib; prognosis; ADVANCED HEPATOCELLULAR-CARCINOMA; POST-PROGRESSION SURVIVAL; ALBUMIN-BILIRUBIN GRADE; INVERSE PROBABILITY; SORAFENIB; MANAGEMENT;

D O I：

10.1002/cam4.4854

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim A comparison of therapeutic efficacy between atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib treatment given as first-line therapy for unresectable hepatocellular carcinoma (u-HCC) in regard to progression-free survival (PFS) overall survival (OS) has not been reported. We aimed to elucidate which of those given as initial treatment for u-HCC has greater prognostic impact on PFS and OS of affected patients, retrospectively. Materials/Methods From 2020 to January 2022, 251 u-HCC (Child-Pugh A, ECOG PS 0/1, BCLC-B/C) treated were enrolled (Atez/Bev-group, n = 194; lenvatinib-group, n = 57). PFS and OS were analyzed following adjustment based on inverse probability weighting (IPW). Results There was a greater number of patients with macro-vascular invasion in Atez/Bev-group (22.7% vs. 8.8%, p = 0.022). In lenvatinib-group, the frequencies of appetite loss (38.6% vs. 19.6%, p = 0.002), hypothyroidism (21.1% vs. 6.7%, p = 0.004), hand foot skin reaction (19.3% vs. 1.0%, p < 0.001), and diarrhea (10.5% vs. 4.6%, p = 0.012) were greater, while that of general fatigue was lower (22.8% vs. 26.3%, p = 0.008). Comparisons of therapeutic best response using modified response evaluation criteria in solid tumors (mRECIST) did not show significant differences between the present groups (Atez/Bev vs. lenvatinib: CR/PR/SD/PD = 6.1%/39.1%/39.1%/15.6% vs. 0%/48.0%/38.0%/14.0%, p = 0.285). In patients of discontinuation of treatments, 48.2% switched to lenvatinib, 10.6% continued beyond PD, 8.2% received another systemic treatment, 5.9% underwent transcatheter arterial chemoembolization (TACE), 3.5% received hepatic arterial infusion chemotherapy (HAIC), and 1.2% underwent surgical resection in Atez/Bev-group, while 42.2% switched to Atez/Bev, 4.4% continued beyond PD, 4.4% received another systemic treatment, 2.2% nivolumab, 6.7% received TACE, and 2.2% received HAIC in lenvatinib-group. Following adjustment with inverse probability weighting (IPW), Atez/Bev-group showed better PFS (0.5-/1-/1.5-years: 56.6%/31.6%/non-estimable vs. 48.6%/20.4%/11.2%, p < 0.0001) and OS rates (0.5-/1-/1.5-years: 89.6%/67.2%/58.1% vs. 77.8%/66.2%/52.7%, p = 0.002). Conclusion The present study showed that u-HCC patients who received Atez/Bev as a first-line treatment may have a better prognosis than those who received lenvatinib.

引用

页码：325 / 334

页数：10

共 41 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib [J].

Ando, Yuwa ;

Kawaoka, Tomokazu ;

Suehiro, Yosuke ;

Yamaoka, Kenji ;

Kosaka, Yumi ;

Uchikawa, Shinsuke ;

Kodama, Kenichiro ;

Morio, Kei ;

Fujino, Hatsue ;

Nakahara, Takashi ;

Murakami, Eisuke ;

Yamauchi, Masami ;

Tsuge, Masataka ;

Hiramatsu, Akira ;

Fukuhara, Takayuki ;

Mori, Nami ;

Takaki, Shintaro ;

Tsuji, Keiji ;

Nonaka, Michihiro ;

Hyogo, Hideyuki ;

Aisaka, Yasuyuki ;

Masaki, Keiichi ;

Honda, Yoji ;

Moriya, Takashi ;

Naeshiro, Noriaki ;

Azakami, Takahiro ;

Takahashi, Shoichi ;

Imamura, Michio ;

Chayama, Kazuaki ;

Aikata, Hiroshi .

ONCOLOGY, 2020, 98 (11) :787-797

[3] Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade [J].

Aoki, Tomoko ;

Kudo, Masatoshi ;

Ueshima, Kazuomi ;

Morita, Masahiro ;

Chishina, Hirokazu ;

Takita, Masahiro ;

Hagiwara, Satoru ;

Ida, Hiroshi ;

Minami, Yasunori ;

Tsurusaki, Masakatsu ;

Nishida, Naoshi .

CANCERS, 2020, 12 (10) :1-13

[4] Management of hepatoceullular carcinoma [J].

Bruix, J ;

Sherman, M .

HEPATOLOGY, 2005, 42 (05) :1208-1236

[5] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[6] Intraindividual Comparison of Gadoxetate Disodium-enhanced MR Imaging and 64-Section Multidetector CT in the Detection of Hepatocellular Carcinoma in Patients with Cirrhosis [J].

Di Martino, Michele ;

Marin, Daniele ;

Guerrisi, Antonino ;

Baski, Mahbubeh ;

Galati, Francesca ;

Rossi, Massimo ;

Brozzetti, Stefania ;

Masciangelo, Raffaele ;

Passariello, Roberto ;

Catalano, Carlo .

RADIOLOGY, 2010, 256 (03) :806-816

[7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[8] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[9] Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome [J].

Fuchigami, Akira ;

Imai, Yukinori ;

Uchida, Yoshihito ;

Uchiya, Hiroshi ;

Fujii, Yohei ;

Nakazawa, Manabu ;

Ando, Satsuki ;

Sugawara, Kayoko ;

Nakayama, Nobuaki ;

Tomiya, Tomoaki ;

Mochida, Satoshi .

PLOS ONE, 2020, 15 (04)

[10] The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study [J].

Hatanaka, Takeshi ;

Naganuma, Atsushi ;

Shibasaki, Mitsuhiko ;

Kohga, Tatsuya ;

Arai, Yosuke ;

Nagashima, Tamon ;

Ueno, Takashi ;

Namikawa, Masashi ;

Saito, Shuichi ;

Hoshino, Takashi ;

Takizawa, Daichi ;

Arai, Hirotaka ;

Makita, Fujio ;

Kakizaki, Satoru ;

Harimoto, Norifumi ;

Shirabe, Ken ;

Uraoka, Toshio .

ONCOLOGY, 2021, 99 (04) :203-214

← 1 2 3 4 5 →